OTC · LGNZZ
Healthcare · Medical - Pharmaceuticals
$0.06
Up+$0.00 (+0.00%)
Updated Aug 27, 2026, 4:50 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
LGNZZ does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning LGNZZ.
LGNZZ research
Company profile and research snapshot.
LIGAND PHARMS BETA CVR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Leerink Partners | Outperform | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | Oppenheimer | Outperform | — |
| Jul 21, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 6, 2026
Adjusted EPS jumps 48% to $2.37, driven by Filspari and Otuber strength, while the transformative Zoma deal adds over 120 assets and $2.3 billion in milestone potential.
Yahoo · Aug 6, 2026
Moby summary of Ligand Pharmaceuticals Incorporated's Q2 2026 earnings call
Yahoo · Aug 6, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year
Yahoo · Aug 6, 2026
Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LGNZZ.
